BioSpace News Archive

ProMIS Neurosciences Inc. today announced a publication identifying Receptor for Activated C-Kinase 1 (RACK1) as a novel misfolded protein target for ALS and frontotemporal lobar degeneration (FTLD).

OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.

Castle Biosciences, Inc. today announced that on Dec. 18, 2023, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 52 employees covering an aggregate of 170,913 shares of common stock as an inducement material to their entering into employment with Castle Biosciences.

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

ImmunoScape and MiNK Therapeutics, Inc today announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors.

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.

Palatin Technologies, Inc. today announced the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million.

Agenus Inc. today announced that data from an investigator sponsored trial (IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune activator) in combination with balstilimab (BAL, PD-1 antibody) in neoadjuvant colorectal cancer (CRC) will be presented at the upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San Francisco.

Genascence Corporation today announced that Thomas Chalberg , Ph.D., founder and chief executive officer, will present a corporate update at the Biotech Showcase 2024 being held January 8-10, 2024 in San Francisco, CA.